Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
| ▸ | PDXK | O00764 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | ACP1 | P24666 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948150 | 0.77 | — | — | |
| SCHEMBL14944841 | 0.72 | ADRB2 (0.32) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL13971486 | 0.69 | — | — | |
| SCHEMBL5666549 | 0.67 | PNPO (0.38) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL8835556 | 0.64 | KDM4E (0.59) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL13972053 | 0.64 | MME (0.32) | — | |
| SCHEMBL8265770 | 0.63 | KDM4E (0.62) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL11013377 | 0.62 | PDXK (0.44) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL9656230 | 0.61 | KDM4E (0.45) | KDM4EMEN1ALDH1A1LMNAHPGD | |
| SCHEMBL29952515 | 0.59 | KDM4E (0.49) | KDM4EMEN1ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | KDM4E 729/4885MEN1 127/4885ALDH1A1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.